FDA Clears Zynex’s TensWave for Transcutaneous Electrical Nerve Stimulation Therapy

Image Credit: Adobe Stock Images/Aleksej

The FDA has granted clearance to Zynex’s new TensWave device, designed to provide drug-free pain relief through TENS (transcutaneous electrical nerve stimulation) therapy. According to the company, the device offers a portable, user-friendly solution for chronic and acute pain management. While not intended to replace Zynex’s flagship NexWave electrotherapy device, Zynex states that TensWave complements NexWave by catering to patients with insurance plans that specifically cover TENS therapy.¹

"The introduction of TensWave aligns perfectly with our commitment to providing comprehensive pain management solutions," said Thomas Sandgaard, CEO, Zynex Medical, in a press release. "We recognized a gap in the market for a high-quality TENS device that meets the specific criteria for insurance reimbursement, and TensWave is our answer to that demand. It complements our flagship multi-modality device, the NexWave, where Interferential current is the main modality and driver of obtaining prescriptions. This device broadens our product portfolio and enhances our support to patients."

Zynex said it expects the TensWave to become an essential tool for patients suffering from chronic pain conditions, explaining that it complements the other offerings of electrotherapy products, cervical traction, braces, cold/hot therapy, and compression devices.¹

Reference

1. Zynex Obtains FDA clearance for new Pain Management Device. Zynex. September 3, 2024. Accessed September 4, 2024. https://zynexmed.investorroom.com/2024-09-03-Zynex-Obtains-FDA-clearance-for-new-Pain-Management-Device